136 related articles for article (PubMed ID: 31079534)
1. Serum Urate, Uricase, and Blood Pressure Control in Gout.
Borghi C; Virdis A
Hypertension; 2019 Jul; 74(1):23-25. PubMed ID: 31079534
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS
Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081
[TBL] [Abstract][Full Text] [Related]
3. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
Ganson NJ; Kelly SJ; Scarlett E; Sundy JS; Hershfield MS
Arthritis Res Ther; 2006; 8(1):R12. PubMed ID: 16356199
[TBL] [Abstract][Full Text] [Related]
4. Preparation of PEGylated uricase attached magnetic nanowires and application for uric acid oxidation.
Kilimci U; Uygun DA
J Biotechnol; 2023 Aug; 373():12-19. PubMed ID: 37343601
[TBL] [Abstract][Full Text] [Related]
5. Pegloticase and lowering blood pressure in refractory gout; is it uric acid or hydrogen peroxide?
Fini MA; Stenmark KR
Eur J Intern Med; 2019 Nov; 69():e11-e12. PubMed ID: 31471165
[No Abstract] [Full Text] [Related]
6. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.
Bomalaski JS; Holtsberg FW; Ensor CM; Clark MA
J Rheumatol; 2002 Sep; 29(9):1942-9. PubMed ID: 12233890
[TBL] [Abstract][Full Text] [Related]
7. [Gout: an overview of available urate lowering therapies].
Richette P
Ann Pharm Fr; 2012 May; 70(3):133-8. PubMed ID: 22655581
[TBL] [Abstract][Full Text] [Related]
8. Pegloticase for treating refractory chronic gout.
George RL; Sundy JS
Drugs Today (Barc); 2012 Jul; 48(7):441-9. PubMed ID: 22844655
[TBL] [Abstract][Full Text] [Related]
9. PEG-uricase in the management of treatment-resistant gout and hyperuricemia.
Sherman MR; Saifer MG; Perez-Ruiz F
Adv Drug Deliv Rev; 2008 Jan; 60(1):59-68. PubMed ID: 17826865
[TBL] [Abstract][Full Text] [Related]
10. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
Sundy JS; Becker MA; Baraf HS; Barkhuizen A; Moreland LW; Huang W; Waltrip RW; Maroli AN; Horowitz Z;
Arthritis Rheum; 2008 Sep; 58(9):2882-91. PubMed ID: 18759308
[TBL] [Abstract][Full Text] [Related]
11. Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase.
Kelly SJ; Delnomdedieu M; Oliverio MI; Williams LD; Saifer MGP; Sherman MR; Coffman TM; Johnson GA; Hershfield MS
J Am Soc Nephrol; 2001 May; 12(5):1001-1009. PubMed ID: 11316859
[TBL] [Abstract][Full Text] [Related]
12. A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties.
Nyborg AC; Ward C; Zacco A; Chacko B; Grinberg L; Geoghegan JC; Bean R; Wendeler M; Bartnik F; O'Connor E; Gruia F; Iyer V; Feng H; Roy V; Berge M; Miner JN; Wilson DM; Zhou D; Nicholson S; Wilker C; Wu CY; Wilson S; Jermutus L; Wu H; Owen DA; Osbourn J; Coats S; Baca M
PLoS One; 2016; 11(12):e0167935. PubMed ID: 28002433
[TBL] [Abstract][Full Text] [Related]
13. Reduction of plasma urate levels in the cockerel with polyethylene glycol-uricase.
Abuchowski A; Karp D; Davis FF
J Pharmacol Exp Ther; 1981 Nov; 219(2):352-4. PubMed ID: 7288624
[TBL] [Abstract][Full Text] [Related]
14. Update on emerging urate-lowering therapies.
Chohan S; Becker MA
Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
[TBL] [Abstract][Full Text] [Related]
15. Pegloticase and the patient with treatment-failure gout.
Dave AJ; Kelly VM; Krishnan E
Expert Rev Clin Pharmacol; 2012 Sep; 5(5):501-8. PubMed ID: 23121270
[TBL] [Abstract][Full Text] [Related]
16. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
Baraf HS; Yood RA; Ottery FD; Sundy JS; Becker MA
J Clin Rheumatol; 2014 Dec; 20(8):427-32. PubMed ID: 25417679
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
Sundy JS; Baraf HS; Yood RA; Edwards NL; Gutierrez-Urena SR; Treadwell EL; Vázquez-Mellado J; White WB; Lipsky PE; Horowitz Z; Huang W; Maroli AN; Waltrip RW; Hamburger SA; Becker MA
JAMA; 2011 Aug; 306(7):711-20. PubMed ID: 21846852
[TBL] [Abstract][Full Text] [Related]
18. Pegloticase and chronic gout.
Ea HK; Chales G; Lioté F
JAMA; 2011 Nov; 306(18):1979; author reply 1979-80. PubMed ID: 22068987
[No Abstract] [Full Text] [Related]
19. [Recent advances in gout: pathogenesis, diagnosis, comorbidities, treatment].
Soós B; Szamosi S; Benkő S; Paragh G; Szekanecz Z
Orv Hetil; 2018 Oct; 159(40):1625-1636. PubMed ID: 30277413
[TBL] [Abstract][Full Text] [Related]
20. Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.
Biggers K; Scheinfeld N
Curr Opin Investig Drugs; 2008 Apr; 9(4):422-9. PubMed ID: 18393109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
